Patent · US Active

Pulmonary administration of pyocins for treating bacterial respiratory infections

US12162911B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

The University Court Of tThe University of Glasgow · GB

Inventors

Daniel Walker · Hanover, US
Laura McCaughey · Stronafian, GB

Key dates

Filing date	Feb 23, 2023
Grant date	Dec 10, 2024
Priority date	—
Expiry date	Feb 23, 2043

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The treatment of bacterial respiratory infections using bacterially-originating antibiotics known as pyocins are provided. In particular, S-type pyocins are administered by pulmonary administration for the treatment of bacterial infections such as Pseudomonas aeruginosa infections. Methods of using S-type pyocin proteins, particularly those comprising an S2, SD2, S5 or AP41 targeting portion or an S2, SD2, S5 or AP41 effector portion are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.